









EUROPEAN NANOMEDICINE MEETING



APRIL 2, 2017

18h00 Registration open

APRIL 3, 2017

VANGUARDS IN NANOMEDICINE: NATIONAL RESEARCH PROGRAMMES AND ACTIVITIES

Chair: Professor Andrew Owen

09h00 British Society for Nanomedicine – Professor Steven Conlan, Swansea University Medical School, Swansea, UK

09h15 Société Française de Nanomédecine – Dr Nathalie Mignet, L'Université Paris Descartes, France.

09h30 Platforma Espanola de Nanomedicina – TBC

09h45 Deutsche Platform NanoBioMedizin – Dr Klaus Michael Weltring, Gesellschaft für Bioanalytik, Münster Germany

10h00 NanoMed North - TBC

10h15 Overview of US activities – Professor Mauro Ferrari, Houston Methodist Research Institute, Houston, Texas, US.

10h30 Coffee break



EUROPEAN NANOMEDICINE CHARACTERISATION LABORATORY (EU-NCL) SESSION

Chair: Professor Andrew Owen

10b55	Overview of the EU-NCL	infractructure - D	r Simon Raconnia	r CEA Eranca
101133	Overview of the EU-INCL	. inirastructure – D	ir Simon Baconnie	r. CEA. France

- 11h10 The science underpinning physical characterisation Dr Fanny Caputo, Università di Roma, Italy
- 11h25 The science of chemical characterisation Dr Sven Even Borgos, SINTEF, Norway
- 11h40 The science of biocompatibility testing Dr Neill Liptrott, University of Liverpool, UK
- 11h55 A perspective on nano-regulation from the MHRA Justin Pittaway-Hay, MHRA, UK
- 12h10 Discussion to include Pedro Silva, Justin Pittaway-Hay, Simon Baconnier, Sven Even Borgos, Neill Liptrott, and Fanny Caputo

12h30 POSTER SESSION (Session A) & LUNCH BREAK

APRIL 3, 2017, AFTERNOON

FUNDAMENTAL NANOMEDICINE

Chair Professor Steve Rannard

- 13h30 Polymeric nanomedicines Professor Cameron Alexander, University of Nottingham, UK
- 14h00 Title TBC Professor Yuri Volkov, Trinity College, Dublin, Ireland
- 14h30 Title TBC Maria Vicent, Centro de Investigación Príncipe Felipe, Valencia, Spain
- 15h00 An injectable nanoparticle generator enhances delivery of cancer therapeutics Professor Mauro Ferrari, Texas Medical Center, USA
- 15h30 Coffee break
- 16h00 Selected Communications 1.1
- 16h15 Selected Communications 1.1
- 16h30 Selected Communications 1.1
- 16h45 Sponsor Communication

18h30 Evening entertainment



PRECLINICAL NANOMEDICINE

Chair: Dr. May Azzawi

09h00 Preclinical models to investigate magnetic drug targeting in atherothrombotic disease – Dr Iwona Cicha, Cardiovascular Nanomedicine Unit, University Hospital Erlangen, Germany

09h30 Nanotheranostics for Focused Ultrasound Targeted Drug Delivery – Dr Maya Thanou, Kings College, London, UK

10h00 Nanotechnological surface modification for medical devices – Dr Tomasz Ciach, Warsaw University of Technology, Poland

10h30 Targeted nanomedicines for cancer therapy – Dr Christine Dufès, University of Strathclyde, UK

11h00 Coffee break

11h30 Selected Communications 1.1

11h45 Selected Communications 1.1

12h00 Selected Communications 1.1

12h15 Sponsor Communication

12h30 POSTER SESSION (Session B) & LUNCH BREAK

APRIL 4, AFTERNOON

TRANSLATIONAL NANOMEDICINE

Chair: Professor Chris Scott

13h30 Imaging of Nanoparticles in Rat Lung Tissue by Means of LA-ICP-MS - Dr Michael Sperling, University of Münster, Germany

14h00 Thinking about target product attributes in basic nanomedicine research can smooth the road to translation – Lea Ann Dailey

14h30 Title TBC – Dr Enza Torino, Istituto Italiano di Tecnologia, Italy

15h00 Title TBC – Professor Jörg Meisel, BG-Clinic Bergmannstrost Halle, Germany

15h30 Coffee break

16h00 Selected Communications 1.1

16h15 Selected Communications 1.1

16h30 Selected Communications 1.1

16h45 Sponsor Communication



FUTURE NEEDS FROM NANOMEDICINE

Chair: Steve Conlan

- 17h00 Future direction of nanomedicine therapeutics Professor Chris Scott, Queens University, Belfast, UK
- 17h20 European Technology Platform for Nanomedicine Patrick Boisseau, ETPN, Paris, France.
- 17h40 Pathways in Nanomedicine in the UK Alex Saxon, Research Councils UK, London, UK



NANOMEDTAB-IN SESSIONS

nanomedTAB-In Sessions will take place on 4th April, from 9h00 to 16h00, in parallel to the European Nanomedicine Meeting 2017.

These face-to-face meetings are the entry point for projects selected to benefit from nanomedTAB (http://nanomedtab.eu/), the First European Nanomedicine Translation Advisory Board. nanomedTAB aims to help the most promising projects in Nanomedicine in their translation to the market, through the free of charge guidance of experts with a wide experience in the Biotech and Pharma industries (http://nanomedtab.eu/index.php#experts).

If you feel that you have a Nanomedicine project ready to start its translation to the market, please consider an application to the nanomedTAB (http://nanomedtab.eu/?apply). The ongoing call will be open until 27th February 2017.

